Preliminary program of the

Seventh Symposium on Glycosaminoglycans

June, 1999

Recent Advances in Research and Clinical Application of Glycosaminoglycans and Related Drugs

September 2-4, 1999

Villa Vigoni, Loveno (Como) / Italy

Organizers:

Job Harenberg
1st Department of Medicine
Faculty of Clinical Medicine
University of Heidelberg
Theodor-Kutzer-Ufer
D-68167 Mannheim
Germany

Benito Casu
Istituto Scientifico di Chimica
e Biochimica "G. Ronzoni"
Via G. Colombo, 81
I-20133 Milano
Italy

Giancarlo Agnelli Istituto di Medicina Interna Universitá degli Studi di Perugia Via Enrico dal Pozzo I-06100 Perugia Italy

Welcome to Villa Vigoni!

It is the seventh time that the staff of Villa Vigoni hosts our symposium on glycosaminoglycan-protein binding, biological implications, unresolved issues in venous thromboembolism, heparin-induced thrombocytopenia and standardization of methods for measurement of hirudin. Since the knowledge in this field is expanding, the Italian and German colleagues of this research area decided to include a clinical session on the status and perspectives of the clinical application of antithrombins during the meeting.

At the end of each session we have organized round table discussions on selected topics, as outlined in the program. We would like to invite all participants to discuss and comment on these topics. Manuscripts of the presentations may be published in Seminars in Thrombosis and Hemostasis in a separate volume.

Please do not hesitate to contact the organizers of the symposium in the case of difficulties concerning transportation, accommodation or other problems with regard to the symposium.

We thank Professor Roeck and his collaborators for enabling this symposium.

Job Harenberg Benito Casu Giancarlo Agnelli

	Thursday, September 2nd, 1999		Friday, September 3rd, 1999
Arrival:	until 12.00 a.m.	Session II:	Unresolved issues in venous thromboembolism - towards a consensus
12.30	Lunch in Villa Vigoni		
		Chairmen:	J. W. ten Cate, Amsterdam; G.G Nenci, Perugia; H. Riess, Berlin
Session I:	Glycosaminoglycan-protein binding. Biological implications		
		9.00-9.20:	G. Agnelli, Perugia
Chairmen:	B. Casu, Milano; J. Harenberg, Mannheim		In hospital versus post discharge prophylaxis of venous thromboembolism of high risk surgical patients
14. 00-14.15 :	B. Casu, Milano:		
	Welcome and introduction	9.20-9.40:	C. Kirchmaier, Wiesbaden; H. Wolf, Nuremberg
			Why induces iv LMWH less aXa activity than sc LMWH
14.15-14.40:	M. Petitou, Toulouse		
	Synthetic heparin oligosaccharides. Inhibition of proteins involved in	9.40-10.00:	Discussion - towards a consensus on specific topics
	thrombosis and cell proliferation		to be prepared by the organizers
14.40-15.00:	A. Naggi/G. Torri, Milano	10.00-10.30:	Break
	Modulation of sulfation patterns and protein-binding properties of natural		
	and biotechnological glycosaminoglycans	10.30-11.00:	D. Gulba, Berlin
			Thrombolysis versus anticoagulation in stable pulmonary embolism
15.00-15.20:	M. Hricovini, Bratislava		
	NMH approaches to detect local glycosaminoglycan structures involved in	11.00-11.20:	H. Büller, Amsterdam
	protein binding		In hospital versus home treatment of venous thromboembolism
15.20-15.30:	Discussion		
15.30-16.00:	Break	11.20-11.40:	J. Harenberg, Mannheim
			Fixed dose subcutaneous low-molecular-weight heparin for treatment of
16.00-16.20:	M. Presta, Brescia		recent venous thromboembolism
	Interaction of glycosaminoglycans with fibroblast growth factors		
		11.40-12.00	J. ten Cate, Amsterdam
16.20-16.40:	G. Gambaro, Padova/E. Schleicher, Tübingen		Future perspectives for treatment with LMWH
	Interaction of glycosaminoglycans with transforming growth factor β		
		12.00-12.30	Discussion - towards a consensus on specific topics
16.40-17.00:	S. Alban, Regensburg		to be prepared by the organizers
	Bodyweight adjusted or fixed dose heparin? Pharmacokinetic		
	considerations	Invited discu	ussants: Riess H, Berlin, Wolf H, Nuremberg
17.00-17.30:	General Discussion	12.30-14.00:	Lunch

	Friday, September 3rd 1999		Saturday, September 4th 1999
Session III:	Heparin-induced thrombocytopenia	Session IV:	Standardization of methods for measurement of hirudins -
Moderators:	A. Greinacher, Greifswald; M. Huisman, Leiden; E. Wenzel, Homburg		Open meeting of the Working Group of the ISTH subcommittee
		Moderators:	A. Stemberger, Munich; G. Agnelli, Perugia; F. Markwardt, Erfurt
14.00-14.20:	M. Petitou, Toulouse		
	Pharmacological basis of the interaction between platelets and heparin	9.00-9.20:	J. Harenberg
			Report on behalf of the working group of the meeting of the ISTH in
14.20-14.40:	F. Piovella, Pavia		Washington, August 1999
	Epidemiology of heparin-induced thrombocytopenia		
		9.20-9.40:	G. Nowak, Jena
14.40-15.00:	Discussion - towards a consensus		Biochemical background of determination methods for hirudin
	to be prepared by the organizers		
4-004-00		9.40-10.00:	P. Eichler, Greifswald
15.00-15.30:	Break		Influence of hirudins on different aPTT-reagents
15.30-16.00:	G. Huhle, Mannheim	10.00-10.30:	Discussion: Defining the value of aPTT for determination of hirudin
10,00 10,00	Hirudin antibodies and their biological relevance	10,00 10,00	2 10 movement 2 criming the value of all 1 1 101 movement of the water
	8	10.30-11.00:	Break
16.00-16.20:	A. Greinacher, Greifswald		
	Management of heparin-induced thrombocytopenia	11.00-11.20:	A Spannagl, Munich
			Standardization of the ecarin clotting time for the determination of hirudins
16.20-16.40:	H. Magnani, Oss		
	Treatment of heparin-induced thrombocytopenia with organan	11.20-11.40:	U. Esslinger, Ludwigshafen
16.40-17.00:	M. Huisman, Leiden		Standardization of ecarin clotting time for PEG-hirudin
	Status of clinical development of pentasaccharides		
		11.40-12.00:	G. Huhle, Mannheim
17.00-17.20	D. Gulba, Berlin		Subcutaneous r-hirudin: A practicable alternative in HIT without
	Status of development of PEG-hirudin		thrombosis
17.20-17.40:	Discussion - towards a consensus	12.00-12.30:	Discussion - Strategies to define the therapeutic value of hirudins
17.20-17.40.	to be prepared by the organizers	12.00-12.50.	Discussion - Strategies to define the therapeutic value of influents
	or to test many of mine or Summone	Invited discu	ussants: Gray E, Hertfordshire; Meuleman DG, Oss;
Invited discu	ssants: Wenzel E, Homburg,; Seifried E, Frankfurt		
	-	12.30:	End of the symposium
19.30:	Dinner		Lunch

General Information

Planned Publication: Seminars in Thrombosis and Hemostasis

Social Program

Thursday, September 2nd 1999

19.3.0 Dinner in Villa Vigoni

Friday, September 3rd, 1999

8.00-8.45 Breakfast

13.00 -14.00 Lunch in Villa Vigoni19.30: Dinner in Villa Vigoni

Saturday, September 4th 1999

8.00-9.00: Breakfast

13.00 -14.00 Lunch in Villa Vigoni

Departure: after lunch

Location of the Symposium:

"Villa Vigoni e.V."

Via Giulio Vigoni 1

Loveno di Menaggio

I-22017 Menaggio (Como)

Tel.: +39-344/361 11 Fax: +39-344/36 12 10

Registration: Thursday, September 2nd, 1999

Scientific correspondence:

Job Harenberg
1st Department of Medicine
Faculty of Clinical Medicine
University of Heidelberg
Theodor-Kutzer-Ufer
D-68167 Mannheim
Germany

Tel: +49/621/383-33 78, -27 89

Fax: +49/621/383-38 08

Email: J-Harenberg@t-online.de